摘要:The heterogeneity of lymphomas results in a wide therapeutic options including both autologous and allogeneic hematopoietic stem cell transplantation (allo-HSCT). We reviewed the role of allo-HSCT in a high-risk group of aggressive non-Hodgkin lym- phoma patients such as those with relapsed or refractory disease, especially after au- tologous HSCT. Moreover, we have analyzed the different modalities of conditioning with myeloabla- tive, reduced-intensity or non-myeloablative regimens, considering their pro and con- tra, in order to highlight the best approach with allo-HSCT for different scenarios